Medicine and Healthcare

2023 Magic Quadrant Apprentice ranks as a Visionary in the 2023 Magic Quadrant for manufacturing Execution Systems JERSEY CITY, N.J., May 3, 2023 (Newswire.com) ...

Sifter technology is helping Ayble Health deliver a best-in-class dietary support tool for people with IBS, IBD, and other GI conditions ...

HOLLYWOOD, Fla., May 3, 2023 (Newswire.com) - Point-of-Care Partners (POCP), a leading health IT management consulting firm, is pleased to announce the additi...

Award Recognizes Domico Med-Device for its Innovative Patient Interface Solutions, Business Growth & Contributions to the Michigan Economy

FENTON, Mich., May 3, 2023 (Newswire.com) - Domico Med-Device LLC, designer and manufacturer of industry-leading patient interface solutions, was named one of Michigan's 50 Companies to Watch at the 19^th Annual Michigan Celebrates Small Business Gala held on May 2, 2023.

The award recognizes high-performance, innovative small businesses that make an astounding impact on Michigan's economy. Nominated by business leaders at the Flint and Genesee Chamber of Commerce, Domico Med-Device fits that mold by developing life-changing medical devices that serve patients and caregivers through diagnostic imaging, image-guided therapy and surgical applications. 

"We are incredibly honored to receive the Michigan 50 Companies to Watch award. It is flattering to be nominated by an outside peer for the progress and growth we have made building our business," said Michael Czop, President of Domico Med-Device. "We're also grateful for the work the Domico Med-Device employees provide in driving the growth of our company. Receiving the award is a testament to the great work our employees do every day in delivering life-changing patient interface solutions." 

Founded in 2018, Domico Med-Device is among Michigan's growing economic engines with over 100 employees and exciting prospects for growth into the future. The company partners with original equipment manufacturers, distributors and healthcare professionals to develop pioneering solutions that promote patient safety and comfort, improve staff productivity and increase medical system utilization.  

Michigan Celebrates Small Business selected Domico Med-Device as one of 80 total awardees (from a pool of more than 500 nominees) honored at the gala, which has served as the state's premier small business awards program since 2005. The organization's mission is to honor and recognize Michigan's small business people and those champions and advocates that support them. 

For the complete list of awardees, visit: https://michigancelebrates.org/mcsb-awardees/ 

For more information on Domico Med-Device, visit: https://www.domicomed.com/ 

Domico Med-Device LLC designs and manufactures industry-leading, life-changing patient interface solutions for diagnostic imaging, image-guided therapy and surgical applications. FDA and ISO registered, Domico Med-Device partners with OEMs, distributors and healthcare professionals from concept to market, leveraging its broad range of capabilities to develop innovative solutions that promote patient safety and comfort, improve staff productivity and increase medical system utilization. Learn more about Domico Med-Device at DomicoMed.com. 

Contact Information:
Erin Hoffman
Director of Human Resources
[email protected]
810-931-8068


Original Source: Domico Med-Device Named One of Michigan's 50 Companies to Watch in 2023

The partnership will provide an innovative virtual cardiac recovery service for their patients across Southern Nevada LAS...

Compass Health Center's Oak Brook location has opened its new Obsessive Compulsive Disorder (OCD) & Complex Anxiety Program for children ages 8-13.

CHICAGO, May 2, 2023 (Newswire.com) - According to recent data collected by the Centers for Disease Control (CDC) between 2016-2019, more than 5.8 million children between the ages of 3-17 in the United States had been diagnosed with an anxiety disorder. These numbers have only increased since the start of the pandemic. In response to this need, Compass Health Center's Oak Brook location has opened its new Obsessive Compulsive Disorder (OCD) & Complex Anxiety Program for children ages 8-13.

This new program complements Compass's Adolescent program for ages 13-18 and supports children whose OCD and other more complex anxiety symptoms persistently interfere with daily functioning. In children, these diagnoses often present as refusal to leave home or attend school, refusal to participate in the classroom, excessive worry, sleep disturbances, and physical health concerns like chronic headaches and stomachaches.

"Since opening our doors to the child population in the West suburbs, we have seen the continued need for more specialized treatment when it comes to OCD and other anxiety disorders. We are excited to offer a more tailored approach to treating OCD and Anxiety with Exposure and Response Prevention (ERP). Having recently launched this specialty in our Adolescent Program, we have seen improved outcomes with these patients and their families and look forward to offering this to our child patients and families as well," said Katrina Shannon, LMFT, Director of Child and Adolescent Programs, Compass Health Center - Oak Brook. 

Compass's evidence-based OCD and Complex Anxiety Partial Hospitalization (PHP) and Intensive Outpatient (IOP) programming introduces children to exposure therapy, one of the most effective treatments for OCD and other anxiety disorders, such as Separation Anxiety Disorder, Social Anxiety Disorder, and Panic Disorder. In addition to attending group and family therapy sessions, children in the program meet with dedicated exposure therapists to address their fears and the avoidance strategies the patients have adopted to manage their fears.  

Children are taught to recognize the negative impact these avoidance strategies are having on their lives and are supported in gradually decreasing their avoidance behaviors. As the child slowly comes into contact with their fears, they learn to function in the presence of their fears and eventually to think about their fears differently. As part of Compass's individualized care model, children participate in family therapy with one or more of their family members, allowing for the family to learn how best to support their anxious child and how not to support their avoidance strategies. 

Ninety percent of Compass's child program participants successfully complete the program and experience a significant reduction in anxiety symptoms. In addition, 95 percent of children in Compass programming avoid hospitalization due to mental health symptoms.  

"We successfully treat these symptoms and diagnoses in our specialty programs for adolescents and adults in Oak Brook and for all ages at our other locations. We are excited to expand these services in a specialized way to children as young as 8 years old and their families in the communities served by our Oak Brook location," said Kerry Lusignan, LCSW, Chief Clinical Officer, Compass Health Center - Oak Brook. 

Compass's expert clinical team of masters-level clinicians understands and focuses on the individualized approach to treatment, which helps children in moving towards achieving a meaningful and functional life. Learn more: https://compasshealthcenter.net/  

Contact Information:
Britt Teasdale
Associate Director, Brand Management, Compass Health Center
[email protected]
Phone 216-926-0550


Original Source: Compass Health Center Launches OCD & Complex Anxiety Program for Children in Western Suburbs to Address Youth Mental Health Crisis

PolarSeal®, a leading medical device contract manufacturer and flexible material converter, is pleased to announce the launch of its new Training Academy - "Operational Excellence" - a training program designed to enha...

TEL AVIV, Israel, May 2, 2023 (Newswire.com) - Imagene, an emerging leader in the field of AI-based precision oncology, is proud to announce its win of the Frost & Sullivan 2023 Europe Technology Innovation Leadership Award in AI-based molecular testing for cancer diagnosis.

Frost & Sullivan Best Practices awards recognize companies for demonstrating outstanding achievement and superior performance in leadership and technological innovation. Imagene AI has been acknowledged for its groundbreaking technology and commitment to innovation and creativity in supporting physicians and patients.

Ashish Kaul, industry analyst at Frost & Sullivan, said, "Imagene's AI-based molecular testing technology scales to streamline cancer care processes and needs. It accelerates cancer diagnosis via accurate, image-based, immediate biomarker profiling, overcoming existing barriers and revolutionizing the market. Frost & Sullivan anticipates rapid, widespread technology adoption."

Imagene AI's technology can detect a wide range of cancer biomarkers in real-time, generating immediate genomic insights from digitized biopsy images alone. By reducing the time-to-results of molecular testing from several weeks to minutes, Imagene's AI-based solution transforms cancer diagnosis and advances precision medicine.

"We are honored to receive this prestigious award from Frost & Sullivan, which validates our dedication to delivering world-class AI-based molecular testing solutions for cancer diagnosis," said Dean Bitan, Co-founder and CEO of Imagene. "Our mission is to provide healthcare professionals with immediate and accurate biomarker profiling, empowering them with crucial information that enables optimal navigation in the complex cancer diagnosis process. This recognition affirms our commitment to innovation and to helping cancer patients in getting the most optimal treatment medicine can offer."

Frost & Sullivan recognizes the high value and accuracy levels of Imagene's AI-based molecular diagnosis solution and its strategic partnerships with leading medical centers and pharmaceutical companies worldwide. Imagene's technology also supports pharmaceutical companies' drug research and development activities, enabling optimal patient stratification for clinical trial optimization.

With its strong overall performance and dedication for bringing value to physicians and patients, Imagene AI is poised to set new market trends and address unmet needs in cancer care. The Frost & Sullivan 2023 Europe Technology Innovation Leadership Award recognizes Imagene's ongoing excellence and pioneering leadership role in the AI-based molecular testing for cancer diagnosis market.

About Imagene

Imagene is an emerging leader in the field of AI-based precision oncology, leveraging AI to profile, in real-time, a broad range of cancer biomarkers from a digitized biopsy image alone. Imagene's AI-based molecular diagnostic solutions streamline cancer care processes and accelerate cancer diagnosis through precise, image-based, immediate biomarkers profiling. 

Imagene is an award-winning diverse BioMed startup with an experienced, passionate and bright team. Our success derives from our cutting-edge technology and multidisciplinary team of data scientists, biologists, software engineers, and medical experts. The company collaborates with top-tier medical centers and pharmaceutical companies worldwide. 

For more information, visit www.imagene.ai.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact Information:
Avital Rabani
Head of Marketing
[email protected]


Original Source: Imagene Wins Frost & Sullivan's Technology Innovation Leadership Award for Its Revolutionary AI-Based Molecular Testing for Cancer Diagnosis